Form 4: Ultragenyx Executive Sells Shares for Tax Withholding

Ultragenyx Pharmaceutical Inc. executive Eric Crombez sold company stock to cover tax obligations related to restricted stock unit vesting.

Summary

• Eric Crombez, EVP and Chief Medical Officer at Ultragenyx Pharmaceutical Inc., reported a transaction involving the sale of common stock.
• The sale occurred on May 5, 2026, for a price of $24.96 per share.
• A total of 344 shares were sold to cover required tax withholdings due to the vesting of Restricted Stock Units (RSUs).
• Following this transaction, Crombez beneficially owns 111,189 shares of common stock.
• The filing also notes the inclusion of 558 shares acquired under the Company's Amended and Restated Employee Stock Purchase Plan on April 30, 2026.
• Previously reported shares of common stock underlying RSUs, subject to vesting conditions, are also included in the beneficial ownership.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. The transaction is a routine tax-related sale of shares by an executive and does not provide new strategic or financial information about the company's performance.

Positives

• The sale was conducted to cover tax withholdings, a standard procedure for executives upon RSU vesting, indicating normal compensation realization.
• The filing includes shares acquired through an Employee Stock Purchase Plan, suggesting employee participation in ownership.
• The reporting person continues to hold a significant number of shares (111,189) after the transaction.

Negatives

• The sale of company stock by an executive, even for tax purposes, can sometimes be perceived negatively by the market.
• The specific reason for the RSU vesting and subsequent tax withholding is not detailed beyond the standard procedure.

Risks

• The filing does not explicitly mention any new or emerging risks.
• Potential future tax implications for executives related to equity compensation remain an ongoing consideration.

Future Outlook

No specific forward-looking statements or guidance are provided in this Form 4 filing, which primarily reports on a completed transaction.

Industry Context

StockSavvy.ai notes that insider transactions like this Form 4 filing are common for executives managing their compensation packages, particularly with equity awards like RSUs. The sale for tax withholding is a routine event and does not inherently signal a change in the executive's or company's outlook.

Stakeholder Impact

• Shareholders: The sale is for tax purposes and does not necessarily indicate a lack of confidence in the company's future. However, any insider selling can be a point of observation.
• Employees: The inclusion of shares acquired through the Employee Stock Purchase Plan suggests ongoing employee engagement with company stock.
• Management: The transaction reflects the standard management of executive compensation and tax liabilities.

Next Steps

• Continued monitoring of insider transactions for any patterns or significant changes in beneficial ownership.
• Review of future SEC filings for updates on Ultragenyx Pharmaceutical Inc.'s financial performance and strategic initiatives.

Key Dates

Keywords

Ultragenyx Pharmaceutical, RARE, Form 4, Insider Transaction, Stock Sale, RSU Vesting, Tax Withholding, Beneficial Ownership, Employee Stock Purchase Plan, Eric Crombez